Source: Frontiers in Oncology. Unidade: FEARP
Subjects: MUTAÇÃO GENÉTICA, NEOPLASIAS MAMÁRIAS, NEOPLASIAS OVARIANAS, PREVENÇÃO DE DOENÇAS
ABNT
LOURENÇÃO, Marina Toledo de Arruda et al. Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies: using real-world data from an upper-middle income country. Frontiers in Oncology, v. 12, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.3389/fonc.2022.951310. Acesso em: 25 nov. 2025.APA
Lourenção, M. T. de A., Galendi, J. S. C., Galvão, H. de C. R., Antoniazzi, A. P., Grasel, R. S., Carvalho, A. L., et al. (2022). Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies: using real-world data from an upper-middle income country. Frontiers in Oncology, 12, 1-12. doi:10.3389/fonc.2022.951310NLM
Lourenção MT de A, Galendi JSC, Galvão H de CR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, Oliveira JHC de, Reis RM, Mandrik O, Palmero EI. Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies: using real-world data from an upper-middle income country [Internet]. Frontiers in Oncology. 2022 ; 12 1-12.[citado 2025 nov. 25 ] Available from: https://doi.org/10.3389/fonc.2022.951310Vancouver
Lourenção MT de A, Galendi JSC, Galvão H de CR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, Oliveira JHC de, Reis RM, Mandrik O, Palmero EI. Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies: using real-world data from an upper-middle income country [Internet]. Frontiers in Oncology. 2022 ; 12 1-12.[citado 2025 nov. 25 ] Available from: https://doi.org/10.3389/fonc.2022.951310
